Arcturus Therapeutics 2025 Q3 Earnings Revenue Beats Expectations, Net Loss Widens 94.8%

Arcturus Therapeutics (ARCT) reported Q3 2025 earnings with a revenue beat of 50.63% but a wider net loss of $13.45 million, driven by reduced collaboration revenue and ongoing operational costs. The stock fell 5.36% post-earnings, reflecting mixed investor sentiment.

Revenue

Collaboration revenue accounted for the bulk of Arcturus’ $17.15 million total revenue, with grant revenue contributing $3 million. This marked a 58.8% decline from the $41.67 million in Q3 2024, primarily due to reduced activity under its CSL partnership.

Earnings/Net Income

The company’s losses deepened to $0.49 per share in Q3 2025, a 94.8% increase in net loss compared to Q3 2024. The EPS shortfall highlights ongoing profitability challenges despite revenue outperforming forecasts.

Post-Earnings Price Action Review

The revenue beat of $17.15 million in Q3 2025, surpassing expectations by 50.63%, spurred a 2.06% post-earnings stock rally to $8.90. While the earnings miss was notable, the company’s strong pipeline in mRNA therapeutics—particularly ARCT-032 for cystic fibrosis and ARCT-2304 for influenza—suggests long-term potential. Cost reductions have extended cash runway into 2028, but a $13.5 million net loss underscores near-term risks. A 30-day holding strategy post-revenue beats appears viable, contingent on regulatory progress and pipeline advancements. Investors should monitor clinical trial updates and management guidance.

[CEO Commentary]

CEO Joseph Payne emphasized confidence in ARCT-032’s potential for cystic fibrosis, citing interim Phase 2 data showing reduced mucus burden. The company plans a 12-week safety trial in 2026.

Additional News

Arcturus faces a securities investigation by Edelson Lechtzin LLP following a 50% stock drop after negative Phase 2 data for ARCT-032. The FDA delayed KOSTAIVE’s U.S. BLA filing due to regulatory shifts, while the vaccine launched in Japan and Europe. Additionally, the company announced cost-cutting measures to extend cash runway, with operating expenses dropping 38% year-to-date.

Guidance

Arcturus reiterated its focus on advancing mRNA therapeutics and vaccines, with ARCT-032 and ARCT-2304 as key programs. The company expects continued collaboration milestones with CSL and anticipates regulatory alignment for pivotal trials in 2026. Cash reserves of $237.3 million support operations into 2028.